J P Morgan Chase & Co reissued their neutral rating on shares of GlaxoSmithKline (LON:GSK) in a research note issued to investors on Wednesday morning. J P Morgan Chase & Co currently has a GBX 1,330 ($17.90) price objective on the stock.

Several other equities analysts also recently weighed in on the company. Societe Generale restated a sell rating on shares of GlaxoSmithKline in a research report on Thursday, November 9th. Berenberg Bank decreased their target price on GlaxoSmithKline from GBX 1,835 ($24.70) to GBX 1,760 ($23.69) and set a buy rating on the stock in a research report on Thursday, November 2nd. Morgan Stanley set a GBX 1,450 ($19.52) target price on GlaxoSmithKline and gave the company a sell rating in a research report on Monday, November 6th. Deutsche Bank set a GBX 1,610 ($21.67) target price on GlaxoSmithKline and gave the company a neutral rating in a research report on Friday, October 27th. Finally, Barclays restated an equal weight rating and issued a GBX 1,450 ($19.52) target price on shares of GlaxoSmithKline in a research report on Friday, October 27th. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus price target of GBX 1,562.86 ($21.03).

GlaxoSmithKline (LON:GSK) traded up GBX 4.50 ($0.06) during midday trading on Wednesday, hitting GBX 1,295 ($17.43). The stock had a trading volume of 15,936,631 shares, compared to its average volume of 10,100,000. GlaxoSmithKline has a 1-year low of GBX 1,270 ($17.09) and a 1-year high of GBX 1,724.50 ($23.21).

GlaxoSmithKline (LON:GSK) last released its earnings results on Wednesday, October 25th. The company reported GBX 32.50 ($0.44) earnings per share for the quarter, beating the consensus estimate of GBX 31.80 ($0.43) by GBX 0.70 ($0.01). The business had revenue of GBX 784.30 billion for the quarter. GlaxoSmithKline had a return on equity of 461.88% and a net margin of 17.79%.

The company also recently declared a dividend, which will be paid on Thursday, January 11th. Stockholders of record on Thursday, November 9th will be given a dividend of GBX 19 ($0.26) per share. The ex-dividend date is Thursday, November 9th. This represents a dividend yield of 1.41%.

In other news, insider Urs Rohner purchased 473 shares of the stock in a transaction dated Wednesday, October 25th. The stock was acquired at an average cost of GBX 1,518 ($20.43) per share, for a total transaction of £7,180.14 ($9,663.71). Also, insider Simon Dingemans purchased 1,076 shares of the stock in a transaction dated Thursday, October 12th. The shares were purchased at an average price of GBX 1,527 ($20.55) per share, with a total value of £16,430.52 ($22,113.76). Over the last 90 days, insiders have bought 1,577 shares of company stock valued at $2,400,086.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://www.watchlistnews.com/glaxosmithkline-gsk-earns-neutral-rating-from-j-p-morgan-chase-co/1767826.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.